Does Zetia Cause Joint Pain?
Yes, joint pain (arthralgia) is a recognized adverse effect of Zetia (ezetimibe), occurring in approximately 10% of patients in clinical trials, both as monotherapy and when combined with statins 1, 2.
Evidence from FDA Labeling and Guidelines
The FDA-approved prescribing information explicitly lists arthralgia (joint pain) among the adverse effects of ezetimibe 2:
- As monotherapy: Upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and pain in extremities
- In combination with statins: Nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, and diarrhea
The 2022 ACC Expert Consensus Decision Pathway confirms these findings, noting that arthralgia appears in both treatment contexts with similar frequency 1.
Clinical Trial Data
Long-term safety studies provide additional context:
- In a 12-month extension study of ezetimibe plus pravastatin (n=436), arthralgia was reported in 10% of patients (43 patients) 3
- In the ezetimibe plus simvastatin study (n=359), arthralgia occurred in 11% of patients (39 patients) 3
These rates are consistent across different statin combinations and appear to be a class effect of ezetimibe rather than an interaction-specific phenomenon.
Important Clinical Distinctions
Joint Pain vs. Muscle Pain
It's critical to distinguish arthralgia from myalgia (muscle pain):
- Arthralgia (joint pain) is a common, generally benign side effect
- Myalgia/myopathy is a more serious concern, particularly when ezetimibe is combined with statins 2
If patients report "joint pain," specifically ask about:
- Location: Is it in the joints themselves or surrounding muscles?
- Associated weakness or tenderness
- Timing relative to medication initiation
When to Worry
The FDA labeling emphasizes that patients should immediately report unexplained muscle pain, tenderness, or weakness, as this may indicate myopathy or rhabdomyolysis—particularly when ezetimibe is combined with statins 2. However, isolated joint pain without muscle involvement is typically benign.
Reassuring Safety Profile
Despite the 10% incidence of arthralgia, the overall safety profile remains favorable:
- Multiple systematic reviews conclude that ezetimibe is "extremely well-tolerated" 4, 5
- The incidence of musculoskeletal adverse events with ezetimibe/statin combinations is no higher than with statin monotherapy 6
- Serious adverse events are rare (<1% considered treatment-related) 3
Clinical Management Algorithm
For patients reporting joint pain on ezetimibe:
Assess severity and characteristics
- Mild, isolated joint discomfort without functional impairment → Continue therapy with monitoring
- Severe or progressive symptoms → Consider dose reduction or alternative therapy
Rule out myopathy
- Check creatine kinase (CK) if any muscle symptoms present
- Discontinue immediately if CK elevated or muscle weakness present
Consider continuation vs. discontinuation
- Joint pain alone (without myopathy) rarely requires discontinuation
- Balance against cardiovascular benefit, especially in high-risk patients
- If intolerable, consider switching to PCSK9 inhibitors or bempedoic acid 7
Bottom Line
Joint pain occurs in approximately 1 in 10 patients taking Zetia, but this is generally mild and does not compromise the drug's favorable benefit-risk profile for cardiovascular risk reduction. The key is distinguishing benign arthralgia from potentially serious myopathy, which requires immediate evaluation and possible discontinuation.